2026-01-26 - Analysis Report
**Company Overview**
Thermo Fisher Scientific Inc. is a global biotechnology company that provides analytical instruments, equipment, software, and services.

**Return Rate Comparison**

* Review Stock (TMO): 110.05%
* Comparison Stock (S&P 500, VOO): 126.41%
* Divergence: -15.50 (Relative Divergence: 30.40%)

**Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 30.0% | 17.2% | 18.0% | 1.1 | 84.1B |
| 2017-2019  | 67.0% | 17.2% | 41.0% | 1.1 | 122.1B |
| 2018-2020  | 80.0% | 23.7% | 56.0% | 0.8 | 175.0B |
| 2019-2021  | 144.0% | 23.7% | 79.0% | 0.8 | 250.7B |
| 2020-2022  | 50.0% | 23.7% | 43.0% | 0.8 | 206.9B |
| 2021-2023  | -48.0% | 26.2% | -69.0% | 0.9 | 199.4B |
| 2022-2024  | -66.0% | 24.5% | -96.0% | 0.9 | 195.4B |
| 2023-2025  | -29.0% | 34.3% | -104.0% | 0.8 | 217.7B |

**Recent Stock Price Fluctuations**

* Close: $625.98
* Last-market change: -2.11%
* 5-day SMA: $627.89
* 20-day SMA: $609.16
* 60-day SMA: $585.98

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence**

* RSI: 63.47
* PPO: 0.22
* MRI: 0.70 (High Investment Recommended)
* Recent (20 days) relative divergence change: 0.70 (+): improving
* Expected Return: 49.50%

**Recent News & Significant Events**

* Recent headlines:
	+ Thermo Fisher (TMO) stock slips from fresh high as earnings week and Fed decision loom - TechStockÂ² (news.google.com)
	+ Whittier Trust Co. Purchases 26,584 Shares of Thermo Fisher Scientific Inc. $TMO - MarketBeat (news.google.com)
	+ Thermo Fisher Scientific's (NYSE:TMO) investors will be pleased with their decent 30% return over the last five years - Yahoo Finance (news.google.com)
	+ How Thermo Fisher and NVIDIA want to turn routine labs into AI powerhouses - Stock Titan (news.google.com)
	+ Thermo Fisher Scientific (TMO) Reports Next Week: Wall Street Expects Earnings Growth - Nasdaq (news.google.com)
	+ Thermo Fisher Chief Operating Officer Michel Lagarde Leaving Company - The Wall Street Journal (news.google.com)

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.54 (~Buy)
- Opinions: 23
- Target Price (avg/high/low): 652.61 / 750.00 / 575.00

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|-----|---:|-------:|
| 2025-10-31 | 4.28 | $11.12 B |
| 2025-08-01 | 4.28 | $10.86 B |
| 2025-05-02 | 3.99 | $10.36 B |
| 2024-11-01 | 4.26 | $10.60 B |
| 2025-10-31 | 4.26 | $10.60 B |

**Financial Information - Revenue and Profitability**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $11.12B | 41.21% |
| 2025-06-30 | $10.85B | 40.61% |
| 2025-03-31 | $10.36B | 40.86% |
| 2024-12-31 | $11.39B | 42.32% |
| 2024-09-30 | $10.60B | 40.84% |

**Financial Information - Capital and Profitability**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.02B | 3.17% |
| 2025-06-30 | $50.51B | 3.20% |
| 2025-03-31 | $49.39B | 3.05% |
| 2024-12-31 | $49.59B | 3.69% |
| 2024-09-30 | $48.99B | 3.33% |

**Comprehensive Analysis (Summary of previous items)**

* Thermo Fisher Scientific Inc. has a cumulative return of 110.05%, lower than the S&P 500's 126.41%.
* The company's Alpha and Beta values vary across different periods, indicating changing market performance.
* Recent stock price fluctuations show a decline in the last market session, but the 5-day SMA is higher than the current price.
* RSI and PPO index indicators suggest a potential buy signal, but the MRI indicates a medium investment risk.
* Analyst consensus is Buy, with a target price of $652.61.
* Recent earnings analysis shows increasing revenue but variable EPS across different quarters.
* Financial information indicates stable profitability and capital structure, with ROE ranging from 3.05% to 3.69%.
* Given the mixed signals, investors should carefully consider Thermo Fisher's performance before making investment decisions.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.